Cytogen (Princeton, NJ) has announced that Michael D. Becker has been promoted to vice president, investor relations officer. Before joining the company in April 2001 as vice president of investor relations and corporate communications, he was a biotechnology analyst at Wayne Hummer Investments as well as founder and editor of Beck on Biotech, a monthly investment newsletter.

Thomas Bucknum has been appointed executive vice president and general counsel at Biogen (Cambridge, MA). He joined the company in 1996, and was named vice president and general counsel in 1999. In addition, Biogen has named Peter N. Kellogg executive vice president, finance, and CFO. Mr. Kellogg joined Biogen in July 2000 as vice president, finance, and CFO.

Scion Pharmaceuticals (Medford, MA) has announced the appointment of Pravin R. Chaturvedi as president and chief executive officer. Dr. Chaturvedi was most recently responsible for lead evaluation at Vertex Pharmaceuticals.

Paul Cossum has been named executive vice president of drug development at NewBiotics (San Diego, CA). Dr. Cossum previously served as vice president of preclinical R&D and business development at Aronex Pharmaceuticals.

Chromos Molecular Systems (Burnaby, BC, Canada) has announced three executive appointments: Ross Durland, previously senior director of preclinical development at Valentis, joins the company as vice president, research and development. Jan Drayer, Chromos' vice president of R&D, assumes the role of chief medical officer. And Eileen Utterson, vice president, corporate development, moves from Chromos to Agrisoma Biosciences, Chromos' subsidiary company, as executive vice president.

Mark E. Furth has joined Incara Pharmaceuticals (Research Triangle Park, NC) as senior vice president, research. Dr. Furth was previously chief scientific officer at PPD Discovery and PPGx.

James M. Gower has been elected to the newly created position of chairman of the board of Rigel Pharmaceuticals (S. San Francisco, CA). He will continue to serve as CEO. In addition, Brian C. Cunningham, Rigel's senior vice president, chief operating officer, and chief financial officer for the last three years, has been promoted to president, and James H. Welch has been promoted to vice president, CFO, and corporate secretary. Mr. Welch joined the company in 1999 and has served as vice president, finance and administration, and assistant secretary.

CombinatoRx (Boston) has announced the appointment of three new executives: Joanna Horobin, previously vice president of oncology at Rhône-Poulenc Rorer (now Aventis), joins the company as executive vice president and chief operating officer. Peter Elliott, from Millennium Pharmaceuticals, joins as senior vice president of product development. Finally, Richard Pops, CEO of Alkermes since 1991, becomes a member of the CombinatoRx board of directors.

Jin Sun Kim has been appointed to the newly created position of vice president of Paradigm Genetics' (Research Triangle Park, NC) human health care group. Ms. Kim was most recently senior vice president, strategic development, and general counsel for Medicis Pharmaceutical. Paradigm also appointed Ian J. Mehr, formerly business director for Laboratory Corporation of America, as director of business development, human health.

BioStratum (Research Triangle Park, NC) has named Seymour Mong vice president of research. Dr. Mong co-founded and most recently held the position of vice president of biotechnology at Structural BioInformatics.

Neose Technologies (Horsham, PA) president, chief operating officer, and CFO P. Sherrill Neff has resigned his executive positions in order to become a founding partner of Quaker Health Ventures, a $250 million life sciences venture fund. Mr. Neff will remain a member of Neose's board of directors. In addition, Stephen Roth, Neose's chairman and CEO, will serve as a member of the advisory board of Quaker Health Ventures.

Richard P. Powers has been appointed vice president and chief financial officer at Corgentech (Palo Alto, CA). He joins the company from Eclipse Surgical Technologies, where he served as its executive vice president and CFO.

Vertex Pharmaceuticals (Cambridge, MA) has named Ian F. Smith to the newly created position of chief financial officer. Mr. Smith joins the company from Ernst & Young, where he served as a partner in the life science and technology practice.